Long

Name: Horny goat weed
Brand: Horny goat weed
Availability: InStock
Rating: 5.0 (1 reviews)

What are post-COVID conditions (long COVID)?

COVID-19 (coronavirus disease 2019) is an illness caused by a virus. Many people get better within a few days or weeks after being infected with the virus. But others have post-COVID conditions. They may:

Have symptoms that linger for weeks, months, or even years
Seem to recover from COVID-19 but then see their symptoms return
Develop new symptoms or new health conditions within a few months of having COVID-19

There are several other names for post-COVID conditions. It is often called long COVID. But it can also be called long-haul COVID, long-term effects of COVID, chronic COVID, post-acute COVID-19, and post-acute sequelae of SARS-CoV-2 (PASC).

Who is more likely to develop post-COVID conditions (long COVID)?

Anyone who had COVID-19, whether it was severe or mild, can have long-lasting symptoms. But you are at higher risk of post-COVID conditions if you:

Had severe COVID-19 illness, especially if you were hospitalized or needed intensive care.
Had underlying health conditions before you got COVID-19.
Did not get a COVID-19 vaccine.
Had multisystem inflammatory syndrome (MIS) during or after COVID-19. MIS is a rare but serious condition in which different body parts become inflamed.

What are the symptoms of post-COVID conditions (long COVID)?

Post-COVID conditions do not affect everyone the same way. They can cause various types and combinations of symptoms in different people. The symptoms may affect different parts of the body, for example:

General symptoms, such as fatigue and fever
Respiratory symptoms, such as trouble breathing and cough
Heart symptoms, such as chest pain and palpitations
Neurologic symptoms such as trouble thinking and concentrating ("brain fog"), headaches, and sleep problems
Digestive symptoms such as diarrhea and stomach pain

Some people may have a wide variety of symptoms that are similar to those of other conditions, such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

Most people's symptoms slowly improve over time. But for some people, the symptoms can last weeks, months, or longer. Sometimes the symptoms are severe enough to result in disability.

How are post-COVID conditions (long COVID) diagnosed?

There is no specific test for post-COVID conditions. To find out if you have a post-COVID condition, your provider:

Will ask about your medical history. This includes asking if you have had a diagnosis of COVID-19, either based on a positive test, symptoms, or exposure.
Will do a physical exam.
May order blood and imaging tests.

Some of symptoms of post-COVID conditions may be hard to explain. The results of blood and imaging tests may be normal. And people who have unexplained symptoms may sometimes be misunderstood by their providers. So it can take some time to get a diagnosis.

What are the treatments for post-COVID conditions (long COVID)?

There is no specific treatment for post-COVID conditions yet. You and your provider can work together to create a personal care plan to manage your symptoms and improve your quality of life.

Can post-COVID conditions (long COVID) be prevented?

The best way to prevent post-COVID conditions is to avoid getting COVID-19. Staying up to date with vaccines (including boosters) against COVID-19 can help prevent COVID-19 infection and protect against severe illness.

Long FDA Approved Drugs

AFREZZA [Insulin Recombinant Human]

12 units/inh (inhalation powder)

4 units/inh (inhalation powder)

8 units/inh (inhalation powder)

Mannkind^{Apr 17, 2015}

Administration of a composition comprising insulin complexed with a diketopiperazine..
Administration of a composition comprising insulin complexed with microparticles of a diketopiperazine..
Administration of fdkp microparticles comprising insulin..
Method of aerosolizing/deagglomerating an insulin dry powder for use in treating diabetes mellitus via oral inhalation using an inhaler with a cartridge containing the insulin dry powder..
Method of controlling glycemia in diabetics by administering an initial dose of insulin-fdkp with a meal; determining blood glucose level 1-2 hrs after and administering a supplemental dose of insulin-fdkp if postprandial glucose level is >140 mg/dl.
Method of delivering to a patient with diabetes mellitus in a single inhalation, greater than 75% of a dry powder dose comprising insulin and fumaryl diketopiperazine using a high resistance to flow dry powder inhaler..
Pulmonary administration of a compisition comprising insulin bound to a diketopiperazine..
Pulmonary administration of a composition comprising insulin bound to a complexing agent..
Pulmonary administration of an insulin composition comprising fdkp at the beginning of a meal to a patient also being treated with a long-acting insulin..
Treatment of a patient having diabetes mellitus with a prandial rapid acting insulin..
Treatment of diabetes mellitus with an inhaled insulin to improve glycemic control using a dry powder inhalation system comprising an inhaler, a cartridge and a dry powder medicament comprising insulin in a single inhalation.
Treatment of patient having diabetes mellitus via oral inhalation of fdkp microparticles comprising insulin.
Use of an inhaler to administer dry powder medicament.

AMITIZA [Lubiprostone^{C₂₀H₃₂F₂O₅}]

24mcg (oral capsule)

8mcg (oral capsule)

Sucampo Pharma Llc^{Jan 31, 2006}

Method for relieving constipation in a human patient that comprises administering to the patient a dosage unit comprising (i) 24mcg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient.
Method for relieving constipation in a patient with opioid-induced constipation that comprises administering to the patient a dosage unit comprising(i)24microg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient.
Method for relieving or treating constipation in a human constipated patient.
Method for relieving or treating constipation in a patient with irritable bowel syndrome.
Method for relieving or treating constipation in a patient with opioid-induced constipation.
Method for the long term treatment of chronic constipation in a human subject with irritable bowel syndrome.
Method for the long term treatment of chronic constipation in a human subject.
Method for treating constipation by opening cic channels in a mammalian subject.
Method for treating constipation in a patient with opioid-induced constipation by opening cic channels.
Method for treating irritable bowel syndrome and method for treating abdominal discomfort associated with irritable bowel syndrome.
Method for treating opioid-induced constipation.
Method of relieving or preventing constipation in a human constipated patient.
Method of relieving or preventing constipation in a human patient with opioid-induced constipation.
Method of treating constipation in a patient with irritable bowel syndrome by opening chloride channels (cic).
Method of treating constipation in a patient with irritable bowel syndrome.
Use in relieving or preventing constipation in a human patient with a dosage unit comprising 24microg+/- 10% of a drug substance and a pharmaceutically suitable excipient.
Use in relieving or preventing constipation in a patient with opioid-induced constipation with a dosage unit comprising 24microg +/- 10% of a drug substance and a pharmaceutically suitable excipient.

ANORO ELLIPTA [Umeclidinium Bromide^{C₂₉H₃₄NO₂Br} : Vilanterol Trifenatate^{C₂₄H₃₃Cl₂NO₅C₂₀H₁₆O₂}]

eq 0.0625mg base/inh : eq 0.025mg base/inh (inhalation powder)

Glaxosmithkline^{Dec 18, 2013}

Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema..

ARCAPTA NEOHALER [Indacaterol Maleate^{C₂₄H₂₈N₂O₃C₄H₄O₄}]

eq 75mcg base (inhalation powder)

Sunovion Pharms Inc^{Jul 1, 2011}

The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.

ARYMO ER [Morphine Sulfate^{2C₁₇H₁₉NO₃5H₂OH₂O₄S}]

15mg (oral tablet, extended release)

30mg (oral tablet, extended release)

60mg (oral tablet, extended release)

Egalet^{Jan 9, 2017}

Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate..

BELBUCA [Buprenorphine Hydrochloride^{C₂₉H₄₁NO₄ClH}]

eq 0.075mg base (buccal film)

eq 0.15mg base (buccal film)

eq 0.3mg base (buccal film)

eq 0.45mg base (buccal film)

eq 0.6mg base (buccal film)

eq 0.75mg base (buccal film)

eq 0.9mg base (buccal film)

Bdsi^{Oct 23, 2015}

Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate..
Treatement of pain by transmucosal delivery of buprenorphine.

BEVESPI AEROSPHERE [Formoterol Fumarate^{2C₁₉H₂₄N₂O₄C₄H₄O₄2H₂O} : Glycopyrrolate^{C₁₉H₂₈NO₃Br}]

0.0048mg/inh : 0.0090mg/inh (inhalation aerosol, metered)

Astrazeneca Pharms^{Apr 25, 2016}

Use in the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd).

BREO ELLIPTA [Fluticasone Furoate^{C₂₇H₂₉F₃O₆S} : Vilanterol Trifenatate^{C₂₄H₃₃Cl₂NO₅C₂₀H₁₆O₂}]

0.1mg/inh : eq 0.025mg base/inh (inhalation powder)

0.2mg/inh : eq 0.025mg base/inh (inhalation powder)

Glaxo Grp Ltd^{May 10, 2013}

For the long-term, once-daily maintenance treatment of airflow obstruction in patients with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in patients with a history of exacerbations.
Indicated for long-term, once-daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in pts with a history of exacerbations.
Indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older.
Long-term, once daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in patients with a history of exacerbations.

BROVANA [Arformoterol Tartrate^{C₁₉H₂₄N₂O₄C₄H₆O₆}]

eq 0.015mg base/2ml (inhalation solution)

Sunovion^{Oct 6, 2006}

For the long term treatment, twice daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema.

BUTRANS [Buprenorphine^{C₂₉H₄₁NO₄}]

10mcg/hr (transdermal film, extended release)

15mcg/hr (transdermal film, extended release)

20mcg/hr (transdermal film, extended release)

7.5mcg/hr (transdermal film, extended release)

Purdue Pharma Lp^{Jun 30, 2010}

Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate..
The management of moderate to severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time.

EMBEDA [Morphine Sulfate^{2C₁₇H₁₉NO₃5H₂OH₂O₄S} : Naltrexone Hydrochloride^{C₂₀H₂₃NO₄ClH}]

100mg : 4mg (oral capsule, extended release)

20mg : 0.8mg (oral capsule, extended release)

30mg : 1.2mg (oral capsule, extended release)

50mg : 2mg (oral capsule, extended release)

60mg : 2.4mg (oral capsule, extended release)

80mg : 3.2mg (oral capsule, extended release)

Alpharma Pharms^{Aug 13, 2009}

Management of pain severe enough to require daily, around-the-clock, long term opioid treatement by orally administering an intact composition as claimed..
Management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed.
Treatment of moderate to severe chronic pain by administering an intact composition as claimed.

FANAPT [Iloperidone^{C₂₄H₂₇FN₂O₄}]

10mg (oral tablet)

12mg (oral tablet)

1mg (oral tablet)

4mg (oral tablet)

6mg (oral tablet)

8mg (oral tablet)

Vanda Pharms Inc^{May 6, 2009}

Dosage modification to reduce risks associated with qt prolongation not induced by other drugs during treatment with iloperidone.
Dosage modification to reduce the risk associated with qt prolongation not induced by other drugs during treatment with iloperidone.
Indicated for the acute treatment of adults with schizophrenia.
Method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are being treated with fluoxetine.
Method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are poor metabolizers of cyp2d6.

HYSINGLA [Hydrocodone Bitartrate^{2C₁₈H₂₁NO₃2C₄H₆O₆5H₂O}]

100mg (oral tablet, extended release)

120mg (oral tablet, extended release)

30mg (oral tablet, extended release)

40mg (oral tablet, extended release)

60mg (oral tablet, extended release)

80mg (oral tablet, extended release)

Purdue Pharma Lp^{Nov 20, 2014}

Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate..

INCRUSE ELLIPTA [Umeclidinium Bromide^{C₂₉H₃₄NO₂Br}]

eq 62.5mcg base/inh (inhalation powder)

Glaxo Grp England^{Apr 30, 2014}

Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema..

INOMAX [Nitric Oxide^NO]

800ppm (inhalation gas)

Mallinckrodt Hosp^{Dec 23, 1999}

A method of providing a predetermined concentration of nitric oxide to a patient.
A method of providing nitric oxide therapy to a patient by compensating long-term sensitivity drift of electrochemical gas sensors used in systems for delivering therapeutic nitric oxide to a patient.
A method of providing nitric oxide therapy to a patient by verifying gas information of nitric oxide prior to delivery to patient.
A method of providing nitric oxide therapy to a patient.
A method of purging a nitric oxide delivery system.
A method of reducing the risk of pulmonary edema in patients in need of treatment with inhaled nitric oxide.
A method of treating hypoxic respiratory failure by verifying gas information of nitric oxide prior to delivery to patient.

LEVEMIR [Insulin Detemir Recombinant]

1000 units/10ml (100 units/ml) (subcutaneous injectable)

Novo Nordisk Inc^{Jun 16, 2005}

Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus.

LEVEMIR FLEXTOUCH [Insulin Detemir Recombinant]

300 units/3ml (100 units/ml) (subcutaneous injectable)

Novo Nordisk Inc^{Oct 31, 2013}

Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus.

NEXIUM [Esomeprazole Magnesium^{2C₁₇H₁₈N₃O₃SMg3H₂O}]

eq 10mg base/packet (oral for suspension, delayed release)

eq 2.5mg base/packet (oral for suspension, delayed release)

eq 20mg base (oral capsule, delayed rel pellets)

eq 20mg base/packet (oral for suspension, delayed release)

eq 40mg base (oral capsule, delayed rel pellets)

eq 40mg base/packet (oral for suspension, delayed release)

eq 5mg base/packet (oral for suspension, delayed release)

Astrazeneca Pharms^{Feb 27, 2008}

Pediatric use aged 1-11 years, gerd and erosive esophagitis.

OXYCONTIN [Oxycodone Hydrochloride^{C₁₈H₂₁NO₄ClH}]

10mg (oral tablet, extended release)

15mg (oral tablet, extended release)

20mg (oral tablet, extended release)

30mg (oral tablet, extended release)

40mg (oral tablet, extended release)

60mg (oral tablet, extended release)

80mg (oral tablet, extended release)

Purdue Pharma Lp^{Apr 5, 2010}

Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate..

SEEBRI [Glycopyrrolate^{C₁₉H₂₈NO₃Br}]

15.6mcg/inh (inhalation powder)

Sunovion Pharms Inc^{Oct 29, 2015}

Long - term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd).

SPIRIVA [Tiotropium Bromide]

eq 0.018mg base/inh (inhalation powder)

Boehringer Ingelheim^{Jan 30, 2004}

Administration of an inhalable powder comprising tiotropium via device.
For the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema.
Treatment of chronic obstructive pulmonary disease.

TROXYCA ER [Naltrexone Hydrochloride^{C₂₀H₂₃NO₄ClH} : Oxycodone Hydrochloride^{C₁₈H₂₁NO₄ClH}]

1.2mg : 10mg (oral capsule, extended release)

2.4mg : 20mg (oral capsule, extended release)

3.6mg : 30mg (oral capsule, extended release)

4.8mg : 40mg (oral capsule, extended release)

7.2mg : 60mg (oral capsule, extended release)

9.6mg : 80mg (oral capsule, extended release)

Pfizer Inc^{Aug 19, 2016}

Management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed.

UTIBRON [Glycopyrrolate^{C₁₉H₂₈NO₃Br} : Indacaterol Maleate^{C₂₄H₂₈N₂O₃C₄H₄O₄}]

15.6mcg/inh : 27.5mcg/inh (inhalation powder)

Sunovion Pharms Inc^{Oct 29, 2015}

Long - term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd).

XTAMPZA ER [Oxycodone^{C₁₈H₂₁NO₄}]

13.5mg (oral capsule, extended release)

18mg (oral capsule, extended release)

27mg (oral capsule, extended release)

36mg (oral capsule, extended release)

9mg (oral capsule, extended release)

Collegium Pharm Inc^{Apr 26, 2016}

Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate..

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.

WARNING: All medicines, drugs, plants, chemicals or medicial precedures below are for reference only. Many of these treatments may be harmful and possibly fatal. Do not consume any plant, chemical, drug or otherwise without first consulting a licensed physician that practices medine in the appropriate field. The owner of this website will not be held liable for any injuries and deaths cause by following any home remedies. We have no control of what is posted.

Home Remedies for Long

IMPOTENCE [erectile dysfunction]
Horny Goat Weed is formulated to bring you the youthful energy you've been longing for. Take consistently for best results.Jerry | November 29th, 2017

STRESS [fatigue]
Frankincense essential oil calms, fights fatigue, and increases circulation. Used with a carrier oil, it helps heal eczema, psoriasis and dandruff, all alongside that lovely scent.IvanTurgenev | July 15th, 2018

ERECTILE DYSFUNCTION - ED [impotence]
The most popular pharmaceutical remedy for ED are Cialis (tadalafil) or Viagra (sildenafil). Both are phosphodiesterase-5 (PDE5) inhibitors for treating impotence. Other drugs to treat erectile dysfunction (ED) include Stendra, Staxyn and Levitra.

Erectile dysfunction can be a symptom of a serious health problem. Consult a physician if you are experiencing impotence over a long period.
Mechanism - phosphodiesterase-5 PDE5 inhibitorsMaryFreeman | May 15th, 2020

SORE THROAT [Pharyngitis]
Horehound (Marrubium vulgare) has been used to treat coughs for a long time. Steep 1 tablespoon of horehound in a cup of boiling water for 15 minutes. Gargle with the strained tea. Sweeten with honey if desired. Alternatively, Horehound cough drops can be purchased commercially. Use as directed.Antonchekov | August 11th, 2020

Reference:

Bergner, Pal., Griswold, Alexandra F., Hufford, David J., et al. . Morton Grove, Il: Publications International, 2017.¹

CARDIOVASCULAR DISEASE [Atherosclerosis]
Olive Oil contains omega-3 and omega-6 fatty acids. Omega-3 are prostaglandins which increase blood flow, reduce inflammation and the formation of blood clots. Three polyphenolic compounds in olive oil, oleuropein, tyrosol and hydroxytyrosol, along with mono-unsaturated fat, may be responsible for preventing LDL cholesterol from being oxidized and sticking to the inner walls of arteries. This is referred to as plaque, which restricts blood flow.
Mechanism - oleuropein, tyrosol, hydroxytyrosolSleslie | August 27th, 2020

Reference:

Brooks, Lisa. . Morton Grove: Publications International, 2017.²

TOE NAIL FUNGUS [Onychomycosis]
The only real "cure" is taking Lamisil (terbinafine hydrochloride) tablets prescribed by a doctor. The longer durations (at weaker doses) allow the nail to grow out. However, this medication can damage your liver. Once the initial infection is under control, brush Vicks Vaporub (or generic) under and around the nail with a toothbrush twice a day to reduce the chance of coming back.Sleslie | July 26th, 2021

Ledgend of Medicine

MODERN MEDICINES

HOME REMEDIES

RANDOM DRUGS

RANDOM AILMENTS

Long

Long FDA Approved Drugs

Home Remedies for Long